Prevention of infection after TAC chemotherapy for node-positive breast cancer as an adjuvant therapy with or without ciprofloxacin

• DOI: 10.1200/jco.2008.26.15_suppl.613
• Publication Date: 2017-02-24T07:33:44Z
• Authors: Y. Suh; C. Chun; S. Oh; B. Song; S. Jung
• Keywords: Leukopenia; Regimen

613 Background: TAC (docetaxel, doxorubicin and cyclophosphamide) chemotherapy has been accepted as an adjuvant for the node positive breast cancer. But, moderate to severe adverse reactions, especially neutropenia, right after this regimen have major hurdle wider enthusiasm. Until now, ciprofloxacin given patients on completion of each cycle prevent systemic infection. We tried determine if is be included in post-chemotherapy medications or not stop possible Methods: randomly assigned 100 into two groups between Jan. 2006 Oct. 2007. Study group (A; n=50 patients, 300 cycles) was prophylactic G-CSF (300 ug) from day 5 10, control (B; n=50, (500 mg, orally twice daily) 10. compared incidence infection neutropenia prospectively. This study reviewed by IRB informed consent patient should compulsory her trial. Results: The A 0.5% B 0.4% (p=0.14). febrile 12% (A) versus 10% (B) (p=0.09). couldn't find significant differences grade 4 nor leukopenia with/without ciprofloxacin. Conclusions: use helpful reduce chemotherapy. Even though larger number enrolled get definite answer delineate protective role against we don't think that itself gives additional advantage having go through all cycles with less reactions. No financial relationships disclose.